LENZ — LENZ THERAPEUTICS INC (Healthcare >> Biotechnology)
LENZ FAQ
What is LENZ's ROE?
LENZ THERAPEUTICS INC reports a Return on Equity (ROE) of -44.22%.
What is LENZ's dividend yield?
LENZ THERAPEUTICS INC offers a dividend yield of 0.00%.
What is LENZ's Deepscope Quality Score?
Deepscope rates LENZ's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LENZ?
Deepscope's AI Timing Score for LENZ is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LENZ belong to?
LENZ THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.72
Price
-0.29
(-4.14%)
Day Change
|
|
|---|
LENZ, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.72 |
| PBV / Sector |
0.89 / 4.75
GREAT
|
| Earning Per Share | -3.33 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
6.26 M
|
| Average 1W Daily Value |
3.22 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-06-09 09:40:02 |
| Symbol | LENZ |
| Name | LENZ THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 31.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 219.79 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075
Phone: 858 925 7000
Website: https://www.lenz-tx.com
Employees: 152
Sector: Healthcare >> Biotechnology
Description: LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google